Literature DB >> 25740780

Comparison of Abbott RealTime HCV Genotype II with Versant line probe assay 2.0 for hepatitis C virus genotyping.

Chen-Hua Liu1, Cheng-Chao Liang2, Chun-Jen Liu3, Chih-Lin Lin4, Tung-Hung Su3, Hung-Chih Yang5, Pei-Jer Chen3, Ding-Shinn Chen6, Jia-Horng Kao7.   

Abstract

Genotyping and subtyping of 225 samples with hepatitis C virus (HCV) genotype 1, 2, 3, or 6 infection were done with Versant LiPA 2.0 and Abbott RealTime HCV Genotype (GT) II by using direct sequencing of the NS5B and 5' untranslated regions as the reference standards. The concordance rates were >99.2% for genotypes and 96.1% for subtypes 1a and 1b. Both the Abbott RealTime and Versant LiPA assays can accurately determine hepatitis C virus genotypes. (This study has been registered at ClinicalTrials.gov under registration no. NCT00979979.).
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Year:  2015        PMID： 25740780      PMCID： PMC4400777          DOI： 10.1128/JCM.03548-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  12 in total

1.  Comparison of DNA enzyme immunoassay and line probe assays (Inno-LiPA HCV I and II) for hepatitis C virus genotyping.

Authors:  S Le Pogam; F Dubois; R Christen; C Raby; A Cavicchini; A Goudeau
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

2.  The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: a 1 year analysis.

Authors:  Marlin Benedet; Dena Adachi; Anita Wong; Sallene Wong; Kanti Pabbaraju; Raymond Tellier; Julian W Tang
Journal:  J Clin Virol       Date:  2014-04-14       Impact factor: 3.168

3.  A multicenter evaluation of the Abbott RealTime HCV Genotype II assay.

Authors:  Marco Ciotti; Fabbio Marcuccilli; Tania Guenci; Muhammed Babakir-Mina; Federico Chiodo; Mose' Favarato; Carlo Federico Perno
Journal:  J Virol Methods       Date:  2010-03-31       Impact factor: 2.014

4.  Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test.

Authors:  J J Germer; P N Rys; J N Thorvilson; D H Persing
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

5.  Comparative study of different methods to genotype hepatitis C virus type 6 variants.

Authors:  Teeraporn Chinchai; Joost Labout; Suwanna Noppornpanth; Apiradee Theamboonlers; Bart L Haagmans; Albert D M E Osterhaus; Yong Poovorawan
Journal:  J Virol Methods       Date:  2003-05       Impact factor: 2.014

6.  Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Rozenn Brillet; Jean-Michel Pawlotsky
Journal:  PLoS One       Date:  2009-12-08       Impact factor: 3.240

7.  Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0.

Authors:  Jannick Verbeeck; Mark J Stanley; Jen Shieh; Linda Celis; Els Huyck; Elke Wollants; Judy Morimoto; Alice Farrior; Erwin Sablon; Margaret Jankowski-Hennig; Carl Schaper; Pamela Johnson; Marc Van Ranst; Marianne Van Brussel
Journal:  J Clin Microbiol       Date:  2008-04-09       Impact factor: 5.948

8.  Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay.

Authors:  Françoise Bouchardeau; Jean François Cantaloube; Stéphane Chevaliez; Christine Portal; Annie Razer; Jean-Jacques Lefrère; Jean Michel Pawlotsky; Philippe De Micco; Syria Laperche
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

9.  Analysis of the 5' noncoding region versus the NS5b region in genotyping hepatitis C virus isolates from blood donors in France.

Authors:  Jean-François Cantaloube; Syria Laperche; Pierre Gallian; Françoise Bouchardeau; Xavier de Lamballerie; Philippe de Micco
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

10.  Hepatitis C virus genotyping: interrogation of the 5' untranslated region cannot accurately distinguish genotypes 1a and 1b.

Authors:  Zhenyu Chen; Karen E Weck
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948
View more
  17 in total

Review 1.  Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Authors:  Eleanor M Wilson; Elana S Rosenthal; Sarah Kattakuzhy; Lydia Tang; Shyam Kottilil
Journal:  Clin Microbiol Rev       Date:  2016-10-19       Impact factor: 26.132

2.  Next-Generation Sequencing: a Diagnostic One-Stop Shop for Hepatitis C?

Authors:  Mario Poljak
Journal:  J Clin Microbiol       Date:  2016-08-10       Impact factor: 5.948

3.  Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.

Authors:  Chen-Hua Liu; Chung-Feng Huang; Chun-Jen Liu; Chia-Yen Dai; Jee-Fu Huang; Jou-Wei Lin; Cheng-Chao Liang; Sheng-Shun Yang; Chih-Lin Lin; Tung-Hung Su; Hung-Chih Yang; Pei-Jer Chen; Ding-Shinn Chen; Wan-Long Chuang; Jia-Horng Kao; Ming-Lung Yu
Journal:  Sci Rep       Date:  2015-07-01       Impact factor: 4.379

4.  Ultra-Deep Sequencing Characterization of HCV Samples with Equivocal Typing Results Determined with a Commercial Assay.

Authors:  Claudia Minosse; Emanuela Giombini; Barbara Bartolini; Maria R Capobianchi; Anna R Garbuglia
Journal:  Int J Mol Sci       Date:  2016-10-07       Impact factor: 5.923

5.  Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.

Authors:  Chen-Hua Liu; Chung-Feng Huang; Chun-Jen Liu; Chia-Yen Dai; Jee-Fu Huang; Jou-Wei Lin; Cheng-Chao Liang; Sheng-Shun Yang; Chih-Lin Lin; Tung-Hung Su; Hung-Chih Yang; Pei-Jer Chen; Ding-Shinn Chen; Wan-Long Chuang; Jia-Horng Kao; Ming-Lung Yu
Journal:  Sci Rep       Date:  2015-10-15       Impact factor: 4.379

6.  NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b.

Authors:  Karin Neukam; Alfredo P Martínez; Andrés C A Culasso; Ezequiel Ridruejo; Gabriel García; Federico A Di Lello
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

7.  Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection.

Authors:  Chen-Hua Liu; Chun-Jen Liu; Tung-Hung Su; Yu-Jen Fang; Hung-Chih Yang; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Open Forum Infect Dis       Date:  2017-02-11       Impact factor: 3.835

Review 8.  HCV Detection, Discrimination, and Genotyping Technologies.

Authors:  Shrikant Dashrath Warkad; Satish Balasaheb Nimse; Keum-Soo Song; Taisun Kim
Journal:  Sensors (Basel)       Date:  2018-10-12       Impact factor: 3.576

9.  Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.

Authors:  Chen-Hua Liu; Wang-Hui Sheng; Hsin-Yun Sun; Szu-Min Hsieh; Yi-Chun Lo; Chun-Jen Liu; Tung-Hung Su; Hung-Chih Yang; Wen-Chun Liu; Pei-Jer Chen; Ding-Shinn Chen; Chien-Ching Hung; Jia-Horng Kao
Journal:  Sci Rep       Date:  2015-11-30       Impact factor: 4.379

10.  Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study.

Authors:  Chen-Hua Liu; Yi-Jie Huang; Sien-Sing Yang; Chung-Hsin Chang; Sheng-Shun Yang; Hsin-Yun Sun; Chun-Jen Liu; Wen-Chun Liu; Tung-Hung Su; Hung-Chih Yang; Chun-Ming Hong; Tai-Chung Tseng; Pei-Jer Chen; Ding-Shinn Chen; Chien-Ching Hung; Jia-Horng Kao
Journal:  Sci Rep       Date:  2018-09-12       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.